FDA Approves “Cold Cap” That Reduces Hair Loss During Cancer Treatment

The U.S. Food and Drug Administration has affirmed another treatment that halfway lightens a standout amongst the most striking impacts of chemotherapy: male pattern baldness.

The treatment is known as the Dignitana DigniCap Cooling System and comprises of a PC controlled gadget that flows chilly fluid to a cooling helmet worn amid chemotherapy treatment. The FDA has cleared it for use in female breast cancer patients only. This was the gathering incorporated into the clinical trial that led to the treatment’s endorsement.

“We are pleased to see a product for breast cancer patients that can minimize chemotherapy-induced hair loss and contribute to the quality of life of these individuals,” Dr. William Maisel,

acting chief of the Office of Device Evaluation in the FDA’s Center for Devices and Radiological Health said in an announcement Tuesday reporting the clearance.

the Dignitana DigniCap Cooling System works by choking veins in the scalp, blocking chemotherapy from entering hair follicles. The treatment, which started in Sweden, is accessible in a few European nations now, Australia, New Zealand, and others.

In the U.S. clinical trial, seven out of 10 patients with early stage breast cancer tumor getting the treatment kept no less than 50 percent of their hair. No unfavorable impacts were accounted for, however, the treatment is just for a solid tumor, not blood-based ones since metastasis in the scalp was a worry.

Donna Tookes was one of the patients taking an interest in the trial in the U.S. The Connecticut inhabitant was determined to have breast cancer disease in January of 2014. In the wake of experiencing a mastectomy of her right breast, she was endorsed chemotherapy. “I didn’t have a choice. There was no option for me,” Tookes told ABC News. “In preparing for chemo, the first thing you think is am I gonna live? Are my children going to be OK? Will they have me in their lives? Then, I will lose my hair.”

Click to comment

Leave a Reply

Most Popular

To Top